Gubra raises guidance: Danish Biotech Weekly (34)

Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc.

In the past week, Gubra raised full-year guidance, SynAct Pharma completed dosing in a phase 2 study, and Scandion Oncology will soon present data from their PANTAX trial at the ESMO Congress 2023. Furthermore, muliple companies also released earnings.

The past week was full of interesting news with 11 of the 20 listed, Danish biotech companies published news. 9 of the 20 companies had a positive development in their share price for the week and 8 companies have had a positive share price performance year to date. Fluoguide overtook Saniona as the best performing stock year-to-date.

Company news the past week

Ascendis Pharma

No news the past week

Biosergen

Interview with Biosergen (in Danish) (Link)

Biosergen is currently raising money via series TO2 warrants and the subscription period ends on August 25 (Link)

Biosergen AB: Biosergen Receives Full Subscription Guarantees for Warrant Exercise from Largest Shareholders and Executive Management (Link)

Cessatech

Cessatech secures DKK 5 million loan facility agreement to support the US launch of its lead program CT001 (Link)

CS Medica

No news the past week

Curasight

No news the past week

Evaxion Biotech

Evaxion Announces Business Update and Second Quarter 2023 Financial Results (Link)

Expres2ion

ExpreS2ion announced financial results for the second quarter 2023 (Link)

Fluoguide

No news the past week

Genmab

Capital Increase in Genmab as a Result of Employee Warrant Exercise (Link)

Gubra

Gubra raises financial guidance for full-year 2023 (Link)

Initiator Pharma

No news the past week

IO Biotech

No news the past week

Pila Pharma

No news the past week

Saniona

Saniona reduces and extends loan (Link)

Saniona executes the set-off issue to Formue Nord (Link)

Scandion Oncology

Data from PANTAX trial to be presented at ESMO Congress 2023 (Link)

SynAct Pharma

SynAct Pharma completes dosing in part A of combined Phase 2a/b RESOLVE study of resomelagon (AP1189) in rheumatoid arthritis (RA) (Link)

ViroGates

ViroGates announces its half-year report for H1, 2023: Revenue is still negatively affected by lower-than-expected sales to clinical routine customers (Link)

Zealand Pharma

Zealand Pharma Announces Financial Results for the First Half of 2023 (Link)

Y-mAbs Therapeutics

No news the past week

2cureX

No news the past week

SELECTED CASES

SHARE PRICE DEVELOPMENTS

On average, the Danish biotech stocks delivered a negative share price performance last week of -2.2%. Gubra became the best performing stock with an 10% after raising the financial guidance for full-yaer 2023. Zealand Pharma also rose 10% after release of their financial report. The best stocks year-to-date include Curasight, Fluoguide, and Saniona after soaring 80-142% even though Saniona took a big hit last week following loan news. Overall the Danish biotech stocks are in negative terrotory this year with a year-to-date return of -0,2% driven by the few companies delivering a positive return.

Read more about Curasight and Fluoguide: The unique cancer treatment of the future – Today’s investment

Overview of share price developments the past week, year-to-date and last twelve months

Disclaimer 

Udvalgte investeringscases

Ønsker du at modtage et af vores nyhedsbreve? Udfyld venligst formularen nedenunder.

  • Investeringscases – Nyhedsbreve med top aktuelle investeringscases fra de nordiske vækstbørser og life science sektoren, og ugentlige markedsopdateringer..
  • Børsnoteringer – Opdateringer på nye og igangværende børsnoteringer i Skandinavien samt resultaterne af dem. (Nyhedsbrev fra Nyemission.dk)   
  • Nyheder – Nyheder fra og om Kapital Partner, herunder indsigt om kapitalmarkederne og børsnoteringer samt invitation til investormøder og- arrangementer.
  • Danish Biotech Weekly – Ugentlig opdatering med nyheder og kursudvikling for alle danske, børsnoterede selskaber uanset hvilket land eller børs de er noteret

*Hvis du ønsker information om vores kommende investeringsforening med fokus på de nordiske vækstbørser, herunder mulighed for at investere, så tilmeld dig nyhedsbrevet Nyheder.




Investornetværk:

Ønsker du at være en del af Kapital Partners investornetværk, hvor du får adgang til investeringer i selskaber og emissioner, samt indbydelse til investorrettede arrangementer
udfyld venligst formularen her.

Udvalgte cases

Del indlægget på sociale media eller på email. 

LinkedIn
Facebook
Twitter
Email